Related Experiment Videos
Antithrombotic therapy for acute myocardial infarction
C J O'Donnell1, P M Ridker, P R Hebert
1Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts 02215, USA.
Journal of the American College of Cardiology
|June 1, 1995
Summary
Aspirin is beneficial for acute myocardial infarction, but adding heparin shows no clear benefit and increases bleeding risk. Further trials are needed to optimize antithrombotic therapy for heart attack patients.
Area of Science:
- Cardiology
- Thrombosis Research
- Clinical Trials
Background:
- Antithrombotic therapy, particularly aspirin, significantly reduces mortality, reinfarction, and stroke in acute myocardial infarction (AMI).
- The optimal antithrombotic regimen for AMI remains controversial, especially regarding the addition of heparin.
- Heparin use with aspirin and thrombolytic therapy has not demonstrated consistent mortality or patency benefits and is associated with increased bleeding risks.
Purpose of the Study:
- To evaluate the optimal antithrombotic regimen for acute myocardial infarction (AMI).
- To compare the risks and benefits of aspirin alone versus aspirin plus heparin in patients not receiving thrombolytic therapy.
- To assess the efficacy and safety of aspirin plus intravenous heparin and aspirin plus intravenous hirudin in AMI.
Main Methods:
- Review of existing randomized trial data on antithrombotic therapy in AMI.
- Analysis of the benefits and risks of aspirin, heparin, and thrombolytic therapy combinations.
- Description of the First American Study of Infarct Survival (ASIS-1) trial design.
Main Results:
- Aspirin provides substantial benefits in reducing mortality, reinfarction, and stroke in AMI patients.
- Adding heparin to aspirin and thrombolytic therapy does not consistently improve outcomes and increases bleeding events.
- Current data are insufficient to compare heparin addition to aspirin alone in patients not receiving thrombolytics.
Conclusions:
- Further large-scale trials are necessary to determine optimal antithrombotic strategies for AMI.
- The balance of benefits and risks for current and novel antithrombotic regimens needs further investigation.
- The ASIS-1 trial will provide crucial data on aspirin, heparin, and hirudin in AMI patients not receiving thrombolytics.